Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515104 | 0.82 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3807159 | 0.77 | DPP4 (0.38) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15401771 | 0.77 | DPP4 (0.43) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2685859 | 0.77 | DPP4 (0.47) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL214373 | 0.72 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL29558815 | 0.72 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL29644108 | 0.68 | DPP4 (0.54) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL31087647 | 0.67 | DPP4 (0.33) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136100 | 0.67 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136102 | 0.67 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889380-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-9587229-B2 | Immobilized transaminases and process for making and using immobilized transaminase | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8293507-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285541-A1 | TRANSAMINASE BIOCATALYSTS | GOT1, GOT2, ENPEP | DPP4 80/4885DPP8 58/4885DPP7 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.